{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:53:34Z","timestamp":1781744014317,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"DOI":"10.1186\/s13023-026-04346-x","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:37:37Z","timestamp":1776926257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of an adult neurofibromatosis clinic in the comprehensive cancer center setting and descriptive analysis of the first 100 patients with neurofibromatosis type 1"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-8516","authenticated-orcid":false,"given":"Lindsay J.","family":"Lipinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Rose","family":"Vater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Goldfinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Belair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Onel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"4346_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","volume":"115","author":"RE Ferner","year":"2013","unstructured":"Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939\u201355.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"4346_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","volume":"70","author":"JM Friedman","year":"1997","unstructured":"Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997;70(2):138\u201343.","journal-title":"Am J Med Genet"},{"issue":"1","key":"4346_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"TJ Lee","year":"2023","unstructured":"Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18(1):292.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4346_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/088307389300800421","volume":"8","author":"K North","year":"1993","unstructured":"North K. Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. J Child Neurol. 1993;8(4):395\u2013402.","journal-title":"J Child Neurol"},{"issue":"4","key":"4346_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ajmg.a.35840","volume":"161A","author":"EC Oates","year":"2013","unstructured":"Oates EC, Payne JM, Foster SL, Clarke NF, North KN. Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge. Am J Med Genet A. 2013;161A(4):659\u201366.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"4346_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/ajmg.a.38680","volume":"176","author":"AB Rietman","year":"2018","unstructured":"Rietman AB, van Helden H, Both PH, Taal W, Legerstee JS, van Staa A, et al. Worries and needs of adults and parents of adults with neurofibromatosis type 1. Am J Med Genet A. 2018;176(5):1150\u201360.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"4346_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/bjc.2016.403","volume":"116","author":"E Uusitalo","year":"2017","unstructured":"Uusitalo E, Kallionp\u00e4\u00e4 RA, Kurki S, Rantanen M, Pitk\u00e4niemi J, Kronqvist P, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer. 2017;116(2):211\u20137.","journal-title":"Br J Cancer"},{"issue":"3","key":"4346_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","volume":"114","author":"AM Vranceanu","year":"2013","unstructured":"Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013;114(3):257\u201362.","journal-title":"J Neurooncol"},{"issue":"10","key":"4346_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jamadermatol.2024.2912","volume":"160","author":"MJ Lin","year":"2024","unstructured":"Lin MJ, Yao H, Vera K, Patel E, Johnson M, Caroline P, et al. Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1. JAMA Dermatol. 2024;160(10):1091\u20138.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"4346_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","volume":"278","author":"DH Gutmann","year":"1997","unstructured":"Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278(1):51\u20137.","journal-title":"JAMA"},{"issue":"7","key":"4346_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(7):671\u201382.","journal-title":"Genet Med"},{"issue":"3","key":"4346_CR12","first-page":"229","volume":"9","author":"TA Gregory","year":"2022","unstructured":"Gregory TA, Molina PSB, Phillips GD, Henson JW. Impact of neurofibromatosis type 1 in an adult community population. Neurooncol Pract. 2022;9(3):229\u201335.","journal-title":"Neurooncol Pract"},{"issue":"1","key":"4346_CR13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12913-018-3471-5","volume":"18","author":"VL Merker","year":"2018","unstructured":"Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018;18(1):668.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"4346_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/cge.12627","volume":"89","author":"HA Crawford","year":"2016","unstructured":"Crawford HA, Barton B, Wilson MJ, Berman Y, McKelvey-Martin VJ, Morrison PJ, et al. Uptake of health monitoring and disease self-management in Australian adults with neurofibromatosis type 1: strategies to improve care. Clin Genet. 2016;89(3):385\u201391.","journal-title":"Clin Genet"},{"issue":"5","key":"4346_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1017\/cjn.2016.326","volume":"44","author":"A Mansouri","year":"2017","unstructured":"Mansouri A, Ghadakzadeh S, Maqbool T, Barnett C, Au K, Kongkham P, et al. Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic. Can J Neurol Sci. 2017;44(5):577\u201388.","journal-title":"Can J Neurol Sci"},{"issue":"8","key":"4346_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834\u201343.","journal-title":"Lancet Neurol"},{"issue":"2","key":"4346_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81\u20138.","journal-title":"J Med Genet"},{"issue":"10","key":"4346_CR18","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00381-020-04708-1","volume":"36","author":"H Toledano-Alhadef","year":"2020","unstructured":"Toledano-Alhadef H, Mautner VF, Gugel I, Zipfel J, Haas-Lude K, Constantini S, et al. Role, function and challenges of multidisciplinary centres for rare diseases exemplified for neurofibromatosis type 1 syndrome. Childs Nerv Syst. 2020;36(10):2279\u201384.","journal-title":"Childs Nerv Syst"},{"key":"4346_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.2147\/JMDH.S362791","volume":"17","author":"S Lalvani","year":"2024","unstructured":"Lalvani S, Brown RM. Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach. J Multidiscip Healthc. 2024;17:1803\u201317.","journal-title":"J Multidiscip Healthc"},{"key":"4346_CR20","unstructured":"About the NFCN. 2025 [Available from: https:\/\/www.ctf.org\/nf-clinic-network]."},{"issue":"11","key":"4346_CR21","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827\u201344.","journal-title":"Neuro Oncol"},{"key":"4346_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/PHMT.S362679","volume":"14","author":"HB Radtke","year":"2023","unstructured":"Radtke HB, Berger A, Skelton T, Goetsch Weisman A. Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care. Pediatr Health Med Ther. 2023;14:19\u201332.","journal-title":"Pediatr Health Med Ther"},{"issue":"17","key":"4346_CR23","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionpaa RA, Poyhonen M, Leppavirta J, Yla-Outinen H, et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol. 2016;34(17):1978\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4346_CR24","doi-asserted-by":"publisher","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","volume":"4","author":"JP Landry","year":"2021","unstructured":"Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, et al. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021;4(3):e210945.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"4346_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/088307380201700804","volume":"17","author":"D Viskochil","year":"2002","unstructured":"Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol. 2002;17(8):562\u201370. discussion 71\u2009\u2013\u20092, 646\u2009\u2013\u200951.","journal-title":"J Child Neurol"},{"key":"4346_CR26","unstructured":"White P, Schmidt A, Shorr J, Ilango S, Beck D, McManus M. Six core elements of health care transition \u2122. Got Transition, The National Alliance to Advance Adolescent Health. 2020(July)."},{"issue":"5","key":"4346_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1212\/01.WNL.0000078813.05925.2C","volume":"61","author":"JM Baehring","year":"2003","unstructured":"Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology. 2003;61(5):696\u20138.","journal-title":"Neurology"},{"issue":"8","key":"4346_CR28","first-page":"4095","volume":"36","author":"RE Friedrich","year":"2016","unstructured":"Friedrich RE, Nuding MA. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature. Anticancer Res. 2016;36(8):4095\u2013121.","journal-title":"Anticancer Res"},{"issue":"2","key":"4346_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.21873\/anticanres.13181","volume":"39","author":"J Mehlan","year":"2019","unstructured":"Mehlan J, Schuttauf F, Salamon JM, Kordes U, Friedrich RE, Mautner VF. Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1. Anticancer Res. 2019;39(2):827\u201331.","journal-title":"Anticancer Res"},{"issue":"2","key":"4346_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00439-021-02410-z","volume":"141","author":"H Kehrer-Sawatzki","year":"2022","unstructured":"Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet. 2022;141(2):177\u201391.","journal-title":"Hum Genet"},{"issue":"11","key":"4346_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1089\/gtmb.2014.0109","volume":"18","author":"R Maruoka","year":"2014","unstructured":"Maruoka R, Takenouchi T, Torii C, Shimizu A, Misu K, Higasa K, et al. The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study. Genet Test Mol Biomarkers. 2014;18(11):722\u201335.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"2","key":"4346_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, et al. The development of cutaneous neurofibromas. Am J Pathol. 2011;178(2):500\u20135.","journal-title":"Am J Pathol"},{"issue":"3","key":"4346_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"CE Prada","year":"2012","unstructured":"Prada CE, Rangwala FA, Martin LJ, Lovell AM, Saal HM, Schorry EK, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012;160(3):461\u20137.","journal-title":"J Pediatr"},{"issue":"1","key":"4346_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0883073817739509","volume":"33","author":"CJ Campen","year":"2018","unstructured":"Campen CJ, Gutmann DH. Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol. 2018;33(1):73\u201381.","journal-title":"J Child Neurol"},{"key":"4346_CR35","doi-asserted-by":"crossref","unstructured":"Toro G, Santoro C, Ambrosio D, Landi G, Scilipoti M, Moretti A, et al. Natural history of scoliosis in children with NF1: an observation study. Healthc (Basel). 2021;9(7).","DOI":"10.3390\/healthcare9070881"},{"issue":"2","key":"4346_CR36","first-page":"135","volume":"173","author":"V Roberti","year":"2022","unstructured":"Roberti V, Miraglia E, Laghi A, Iacovino C, Moliterni E, Giustini S. Tumors in patients with neurofibromatosis type 1: a single-center retrospective study. Clin Ter. 2022;173(2):135\u201340.","journal-title":"Clin Ter"},{"issue":"5","key":"4346_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311\u20134.","journal-title":"J Med Genet"},{"issue":"1","key":"4346_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3892\/ol.2016.4670","volume":"12","author":"D Pan","year":"2016","unstructured":"Pan D, Liang P, Xiao H. Neurofibromatosis type 1 associated with pheochromocytoma and gastrointestinal stromal tumors: A case report and literature review. Oncol Lett. 2016;12(1):637\u201343.","journal-title":"Oncol Lett"},{"key":"4346_CR39","unstructured":"Bureau USC, Population, Estimates. July 1, 2024 [Available from: https:\/\/www.census.gov ]."},{"key":"4346_CR40","unstructured":"Diseases NOfR. Neurofibromatosis 1 [updated April 25. 2022. Available from: https:\/\/rarediseases.org\/rare-diseases\/neurofibromatosis-type-1-nf1\/]."},{"key":"4346_CR41","unstructured":"ESRI, IntelliMed. ESRI Demographic Snapshot: Criteria \u2013 WNY Patient County. In: (ESRI) ESRI, editor. Redlands, CA2025."},{"issue":"4","key":"4346_CR42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ajmg.a.61069","volume":"179","author":"AM Kongkriangkai","year":"2019","unstructured":"Kongkriangkai AM, King C, Martin LJ, Wakefield E, Prada CE, Kelly-Mancuso G, et al. Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1. Am J Med Genet A. 2019;179(4):602\u20137.","journal-title":"Am J Med Genet A"},{"key":"4346_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","volume":"12","author":"CL Monroe","year":"2017","unstructured":"Monroe CL, Dahiya S, Gutmann DH. Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. Annu Rev Pathol. 2017;12:53\u201374.","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"4346_CR44","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167A","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, Baldwin A, Dombi E, Toledo-Tamula MA, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A(9):2103\u201313.","journal-title":"Am J Med Genet A"},{"issue":"Pt 3","key":"4346_CR45","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/brain\/122.3.473","volume":"122","author":"A Cr\u00e9ange","year":"1999","unstructured":"Cr\u00e9ange A, Zeller J, Rostaing-Rigattieri S, Brugi\u00e8res P, Degos JD, Revuz J, et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain. 1999;122(Pt 3):473\u201381.","journal-title":"Brain"},{"issue":"9","key":"4346_CR46","doi-asserted-by":"publisher","first-page":"e065340","DOI":"10.1136\/bmjopen-2022-065340","volume":"12","author":"K Doser","year":"2022","unstructured":"Doser K, Hove H, \u00d8stergaard JR, Bidstrup PE, Dalton SO, Handrup MM, et al. Cohort profile: life with neurofibromatosis 1 - the Danish NF1 cohort. BMJ Open. 2022;12(9):e065340.","journal-title":"BMJ Open"},{"issue":"5","key":"4346_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cge.12551","volume":"88","author":"JS Cohen","year":"2015","unstructured":"Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clin Genet. 2015;88(5):425\u201330.","journal-title":"Clin Genet"},{"issue":"12","key":"4346_CR48","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/jmg-2024-110396","volume":"61","author":"DG Evans","year":"2024","unstructured":"Evans DG, Burkitt-Wright E, Ealing J, Vassello G, Eelloo J, Lee A. Six at Sixty. Malignant peripheral nerve sheath tumours in NF1: 20-year review of a highly cited paper. J Med Genet. 2024;61(12):1132\u20134.","journal-title":"J Med Genet"},{"issue":"3","key":"4346_CR49","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-011-1978-7","volume":"19","author":"CC Stucky","year":"2012","unstructured":"Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878\u201385.","journal-title":"Ann Surg Oncol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04346-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:20:08Z","timestamp":1781742008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04346-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4346"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04346-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were collected prospectively in a secure database following Roswell Park Comprehensive Cancer Center Institutional Review Board approval (protocol I 2348021). The requirement for written informed consent was waived due to the minimal-risk, observational nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no financial or non-financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}